Intelliject is a specialty pharmaceutical company dedicated to developing combination drug/device products that empower patients to control and gain freedom from their medical conditions. Each Intelliject product in development combines an established drug, an innovative delivery platform and a supporting dossier intended to show superiority, patient preference and cost effectiveness data.
Intelliject applies rigorous selection criteria to identify areas where its patient-centric approach and proprietary technology will offer superior solutions. The company only proceeds to an active development program once it has established that incremental clinical and economic benefit is achievable. Intelliject has a focused pipeline of active programs across a number of therapeutic areas, including small molecules and biologics.
Current Team (8)Update
Vice President, Business Development
Chief Science Officer
Vice President, Product Development.
Vice President, Drug Development and Regulatory Affairs
Chief Commercial Officer
Vice President, Industrialization and Quality.
President & CEO
Funding Rounds (2) - $165MUpdate
111 Virginia St.
Richmond, VA 23219